Syngene International Limited — Q4 FY26 earnings call

Call held 30 Apr 2026

Management summary

Syngene International reported a muted 3% YoY top-line growth for FY26, primarily due to the significant impact of Librela destocking, which is expected to continue affecting FY27. Despite this, Q4 showed strong sequential growth of 13%, and the company maintained a robust financial position with healthy free cash flow and a strong net cash balance. Strategic investments in advanced modalities and an extended partnership with Bristol-Myers Squibb are expected to position Syngene for stronger growth from FY28, following a transitional FY27.

Highlights

  • Q4 FY26 delivered a strong 13% sequential growth in top line, reinforcing confidence in underlying business momentum.

  • Syngene generated a healthy INR 521 crores in free cash during FY26, with a closing net cash balance of INR 1,800 crores.

  • Extended long-standing partnership with Bristol-Myers Squibb through to 2035, broadening collaboration scope across the drug development life cycle.

  • Commenced operations at the state-of-the-art antibody drug conjugate discovery laboratory and expanded Bengaluru facility with a GMP bioconjugation suite.

  • Operating EBITDA for Q4 FY26 stood at INR 303 crores with a margin of 29%.

Concerns

  • FY26 closed with a muted top line growth of 3% year-on-year, significantly impacted by Librela destocking.

  • FY27 is expected to be a transition year with broadly flat performance, and Q1 FY27 will have a more pronounced adverse impact of Librela destocking.

  • Reported profit after tax (before exceptional items) for Q4 FY26 was INR 153 crores, down 16% year-on-year.

  • Reported profit after tax (before exceptional items) for FY26 was INR 380 crores, down 20% year-on-year.

  • Incurred a hedge loss of INR 21 crores in Q4 FY26, compared to INR 4.6 crores in the same quarter last year.

Key financials

3 periods

Headline

  • Net Cash Balance (Mar 31, 2026)
    ₹1,800 Cr

Q4

  • Revenue from Operations
    ₹1,037 Cr
    YoY +2% QoQ +13%
  • Operating EBITDA
    ₹303 Cr
  • Operating EBITDA Margin
    29%
  • PAT (before exceptional)
    ₹153 Cr
    YoY -16%

FY26

  • Revenue from Operations Growth
    3%
  • Operating EBITDA Margin
    25%
  • PAT (before exceptional)
    ₹380 Cr
    YoY -20%
  • Free Cash Flow
    ₹521 Cr

What they filed

Q1 FY27: revenue down 15.8%, net profit down 110.4% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue891 944 1,018 875 911 +2%917 −3%1,037 +2%736 −16%
EBITDA245 284 344 206 200 −19%209 −26%303 −12%91 −56%
Net profit106 131 183 87 67 −37%15 −89%148 −19%-9 −110%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Research Services (CRO)
    59% Q4 Revenue Share
  • CDMO
    41% Q4 Revenue Share

Capital allocation

high confidence
  • Capex $10 Mn
    • Research services (capability build and contractual obligations) $5 Mn
    • CDMO business $4 Mn
    • Digitization, automation and common infrastructure $1 Mn
    During the fourth quarter, we invested $10 million – around 50% in research services primarily across capability build and contractual obligations and dedicated centres, along with regular maintenance capex. Nearly 40% of the capex was in CDMO business. The remaining capex was towards digitization, automation and common infrastructure.
  • Debt Net cash ₹1,800 Cr
    • Repayment Borrowing reduced in Q4 '26 compared to the same quarter last year, leading to a 24% decline in interest expense.
    We have a net cash balance of INR1,800 crores as of 31st of March 2026.
  • Liquidity Cash ₹1,800 Cr Strong balance sheet maintained after meeting capex spends.
    We continue to maintain a strong balance sheet after meeting our capex spends for the quarter. We have a net cash balance of INR1,800 crores as of 31st of March 2026.

Guidance & targets

Revenue

  • FY27 Performance Revenue · FY27 · High confidence broadly flat
    Given the current geopolitical uncertainties and the near-term impact of Librela, we expect a broadly flat performance for FY27 while maintaining EBITDA margins in the mid-20s through disciplined cost management and sharper operational execution.

    — Ms. Kiran Mazumdar-Shaw

  • H1 vs H2 FY27 Growth Revenue · FY27 · High confidence H2 meaningfully stronger than H1
    We also expect to start FY27 on a muted note with H2 of FY27 to be meaningfully stronger than H1, with growth weighted towards the second half as new contracts ramp up and business momentum improves.

    — Ms. Kiran Mazumdar-Shaw

  • Growth from FY28 Revenue · FY28 onwards · High confidence stronger growth
    We believe that FY27 will be a year of strategic reset and execution with a healthy pipeline of deal flows that will translate into stronger growth from FY28 onwards.

    — Ms. Kiran Mazumdar-Shaw

  • Librela Impact in FY27 Revenue · FY27 · High confidence almost no Librela in Q1 and Q2, minor volumes towards end of year
    We expect, as Peter alluded a little bit that the coming quarters, quarter 1 and quarter 2 will have almost no Librela. There is some minor Librela volumes towards the end of the year, but that's about it.

    — Mr. Deepak Jain

Profitability

  • FY27 EBITDA Margins Profitability · FY27 · High confidence mid-20s
    Given the current geopolitical uncertainties and the near-term impact of Librela, we expect a broadly flat performance for FY27 while maintaining EBITDA margins in the mid-20s through disciplined cost management and sharper operational execution.

    — Ms. Kiran Mazumdar-Shaw

Business Mix

  • CRO/CDMO Revenue Split Business Mix · next year · Medium confidence broadly two-third CRO, one-third CDMO
    We are anticipating that to be directionally in line for even the next year. So, you would continue the split to be almost similar. There will be minor changes as we continue to evolve through the year. But broadly two-third, one-third is what you can take for your modelling purposes for the moment.

    — Mr. Deepak Jain

What to watch in Q1 FY27

Librela impact on Q1 FY27 revenue

next quarter
Current Significant impact in FY26, expected to continue in Q1/Q2 FY27 with almost no volumes
Target Confirmation of minimal Librela volumes in Q1 FY27 and its specific revenue impact

Why it matters

Librela destocking is a major headwind, and its actual impact on Q1 FY27 will be crucial for assessing the FY27 outlook.

We expect, as Peter alluded a little bit that the coming quarters, quarter 1 and quarter 2 will have almost no Librela.

Risks & concerns

  • Librela destocking impact

    high

    Significant impact on FY26 performance and expected to continue influencing growth in FY27, especially in Q1 and Q2.

    Management acknowledged

  • Geopolitical uncertainties and cost increases

    medium

    Some cost increases observed, but management does not anticipate any material effect on Syngene's business from tariffs or Middle East conflict.

    Management acknowledged

  • Gestation period for new capabilities and facilities

    medium

    New CDMO facilities and capabilities typically take 12-24 months to become operational and contribute meaningfully to revenue, impacting near-term growth.

    Management acknowledged

Q&A highlights

6 direct
Librela impact on FY26 underlying growth and profitability Direct
If we remove Librela from both the years, we have grown as we've always called out. Underlying growth is in single digits. And the impact of Librela is a culmination of what you see in the numbers. ... It's high-single digits.

Clarifies the underlying business performance excluding the significant one-off impact of Librela, indicating a high-single-digit growth.

Asked by Kunal Dhamesha

Librela supply expectations for FY27 guidance Direct
We expect, as Peter alluded a little bit that the coming quarters, quarter 1 and quarter 2 will have almost no Librela. There is some minor Librela volumes towards the end of the year, but that's about it. Most of the Librela impact will be done in this first 2 quarters.

Provides specific timeline for the continued impact of Librela, indicating a significant headwind in the first half of FY27.

Asked by Kunal Dhamesha

Gestation period for new capabilities and facilities (Bayview, Unit 3) Direct
Typically, they do take 12, 18, 24 months depending upon the nature of the site... Unit 3. It took us almost 18-odd months to get it operational and capitalize the site. We would expect the initial trial runs, et cetera, on Bayview to also go through. And then in the coming year, we should start seeing some engineering batches, et cetera, come through and capitalization once we get the regulatory approvals.

Explains the time lag between investment in new facilities/capabilities and their contribution to revenue, setting expectations for future growth drivers.

Asked by Surya Patra

Impact of Section 232 tariffs on CDMO business Direct
Kunal, our assessment of the tariff impact on Syngene is it will be negligible as both the service industry and in the product supplies that we make and supply to our customers. So, we are not anticipating any material effect of tariffs on Syngene's business.

Addresses a potential geopolitical risk, reassuring investors that the tariffs are not expected to materially impact the company's business.

Asked by Kunal Randeria

Bristol-Myers Squibb contract extension and potential for higher revenues Partial
I don't think we can comment in any short-term horizon there. Obviously, if you look at the history of this relationship over the course of years, it has grown, but this is already a substantial business in scale and growth will not be linear in that sense. I think it will grow around U.S. inflation at some level.

While confirming the strategic importance and long-term nature of the partnership, management tempers expectations for immediate, linear revenue growth from this extension.

Asked by Kunal Randeria

Cost increases due to Middle East conflict and ability to pass them through Partial
There have been some cost increases that we've seen in some areas... But I don't think there's any material impact that we're considering at this point in time. And we'll have to wait and see how this resolves going forward.

Acknowledges cost pressures but indicates no material impact currently, with a wait-and-see approach for future resolution.

Asked by Avnish Burman

EBITDA margin guidance discrepancy (cut then beat) Direct
One, for sure, the product mix is a big factor of what made the big swing into our margin structures, right? There was an assumption of what our product mix would be and the cost structures related to that product mix... That went through a bit of a shift, and that was a positive shift in that direction. ... some bit of the cost that's gone into the exceptional items as well that's also led to that change.

Explains the reasons behind the margin performance, attributing it to favorable product mix changes and some costs being reclassified as exceptional items.

Asked by Shyam Srinivasan

AI impact on drug discovery and Syngene's preparedness Direct
I think it is very clear to everybody that the implications of AI in discovery, in development and in manufacturing will be profound... Syngene is moving and accelerating its capabilities to enhance differentiated service value creation to our customers in that field. Kiran, you may want to add something in on this.

Highlights the company's proactive investments and strategic focus on AI to leverage its transformative potential across the value chain.

Asked by Alankar Garude

2 min read 6 chapters

Detailed narrative

FY26 Performance Overview and Librela Impact

Syngene International concluded FY26 with a muted top-line growth of 3% year-on-year, primarily due to the significant impact of Librela destocking. Despite this, the fourth quarter demonstrated strong sequential growth of 13%, with revenue from operations reaching INR 1,037 crores. Operating EBITDA for Q4 stood at INR 303 crores, achieving a 29% margin. However, reported profit after tax (before exceptional items) for FY26 was INR 380 crores, a 20% decline year-on-year, and for Q4, it was INR 153 crores, down 16% year-on-year.

FY27 Outlook and Transition Year

Management anticipates FY27 to be a transition year, projecting broadly flat performance, with EBITDA margins maintained in the mid-20s. The adverse impact of Librela destocking is expected to be most pronounced in Q1 and Q2 FY27, with almost no volumes during this period. Growth is expected to be weighted towards the second half of FY27 as new contracts ramp up, with stronger growth anticipated from FY28 onwards as the company moves beyond the Librela headwind and leverages its strategic investments.

Strategic Investments in New Modalities

Syngene is actively building new capabilities in advanced modalities such as peptides, antibody drug conjugates (ADCs), and oligonucleotides. During Q4, the company commenced operations at its state-of-the-art ADC discovery laboratory, designed to support early-stage research. This facility integrates with existing ADC development and manufacturing capabilities, enabling a seamless pathway from discovery to production. Investments also include a new commercial scale facility for liquid-filled hard gelatin capsules, strengthening oral solid dosage capabilities.

CDMO Business and Bayview Facility Progress

The CDMO business is experiencing an acceleration in pipeline buildup, with increased client interactions at the Unit 3 biologics facility in Bengaluru. Preparations are progressing well at the Bayview biologics facility in the United States, with active engagement with prospective customers for its operationalization this year. While Unit 3 is fully capitalized, Bayview's capitalization is still partial, and management expects to provide further updates on its full operationalization and P&L impact.

Extended Partnership with Bristol-Myers Squibb

A key highlight for the year was the extension of Syngene’s long-standing partnership with Bristol-Myers Squibb through to 2035. This expanded agreement broadens the scope of collaboration across the entire drug development life cycle, including discovery, translational sciences, pharmaceutical development, manufacturing, and clinical research. This extension provides a strategic framework for Syngene to support Bristol-Myers Squibb's evolving pipelines and portfolios, though growth from this partnership is expected to be around US inflation levels rather than linear.

Leadership Transition and AI Focus

Ms. Kiran Mazumdar-Shaw has returned as Executive Chairperson, emphasizing the company's transition into its next phase of growth. The company is also undergoing leadership changes, including new appointments, to strengthen its focus on CDMO operational excellence and partnerships. Syngene is actively investing in AI and digital technologies, with a team of AI scientists working to enhance speed, productivity, predictability, and scale across discovery, development, and manufacturing, aiming to create differentiated offerings for global customers.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls